Skip to main content
SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. logo

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. — Investor Relations & Filings

Ticker · 688238 ISIN · CNE1000059N9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 486 across all filing types
Latest filing 2024-02-07 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688238

About SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD.

https://www.obio-tech.com/

SHANGHAI OBIO TECHNOLOGY (GROUP) CORP., LTD. is a specialized Contract Development and Manufacturing Organization (CDMO) focused on the gene and cell therapy (GCT) sector. The company provides end-to-end solutions encompassing vector construction, process development, analytical method development, and large-scale GMP manufacturing. Its service portfolio includes the production of viral vectors such as adeno-associated virus (AAV), lentivirus, adenovirus, and oncolytic viruses, as well as plasmid DNA and cell therapy products. Obio Technology supports clients from early-stage research through clinical trials to commercialization. The company operates advanced facilities designed to meet international regulatory standards, facilitating the development of innovative genetic medicines and advanced therapies for global biopharmaceutical partners.

Recent filings

Filing Released Lang Actions
第三届监事会第八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the eighth meeting of the third Supervisory Board of Heyuan Biotechnology (Shanghai) Co., Ltd. It details the approval of employee stock ownership plan proposals and management measures, including voting results and references to related documents published on the Shanghai Stock Exchange website. The document is a meeting resolution announcement by the Supervisory Board, not a full report or financial statement. It does not contain financial data or detailed management discussion but rather governance and procedural information about employee stock plans. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies. The document length is short (1955 characters), and it is not merely an announcement of a report publication but a substantive meeting resolution announcement. Hence, the classification is MANG with high confidence.
2024-02-07 Chinese
第一期员工持股计划（草案）
Capital/Financing Update Classification · 95% confidence The document is a detailed draft of an employee stock ownership plan (员工持股计划草案) for a company named 和元生物技术（上海）股份有限公司. It includes comprehensive information about the plan's purpose, principles, participants, funding, stock sources, duration, lock-up periods, management, and governance. It references relevant laws and regulations such as the Company Law, Securities Law, and Shanghai Stock Exchange rules. The document is lengthy (15,000 characters) and contains substantive content about the employee stock ownership plan itself, not merely an announcement or summary. It is not a financial report, earnings release, or regulatory filing. It is a formal plan document related to capital structure and employee incentives. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it relates to company fundraising and capital structure changes through an employee stock ownership plan.
2024-02-07 Chinese
2023年年度业绩预亏公告
Earnings Release Classification · 95% confidence The document is a 2023 annual performance forecast announcement by Heyuan Biotech (Shanghai) Co., Ltd. It provides preliminary estimated financial results for the full year 2023, including expected revenue, net profit, and R&D expenses, with comparisons to the prior year. It explicitly states that the data are preliminary and unaudited, and the final audited results will be disclosed in the formal 2023 annual report. The document length is about 2000 characters, which is relatively short and consistent with an earnings release or performance forecast rather than a full annual report. The content focuses on key financial highlights and expected losses, typical of an earnings release. There is no detailed financial statement or comprehensive analysis that would qualify it as a full Annual Report (10-K). Therefore, the document is best classified as an Earnings Release (ER). FY 2023
2024-01-29 Chinese
关于参与设立产业投资基金暨关联交易进展情况的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about its participation in establishing an industrial investment fund and related progress. It details the fund's registration, partners, capital contributions, and regulatory filings. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory announcement about a capital investment and related party transaction progress, not a financial report or earnings release. It fits best under Capital/Financing Update (CAP) as it concerns the company's investment in a fund and related capital commitments.
2024-01-10 Chinese
上海市金茂律师事务所关于和元生物技术（上海）股份有限公司2023年第二次临时股东大会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by Jin Mao Law Firm regarding the convening, procedures, and results of the 2023 second extraordinary general meeting (EGM) of shareholders of Heyuan Biotechnology (Shanghai) Co., Ltd. It details the legality of the meeting's notice, attendance, voting procedures (both onsite and online), and the final voting results on specific governance-related proposals. The document does not contain financial statements or performance data, nor is it a report of financial results or management discussion. It is a formal legal opinion on the conduct and validity of a shareholders' meeting and its resolutions. This type of document is best classified as a Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results and confirms the legitimacy of the shareholder meeting and its decisions.
2023-12-26 Chinese
2023年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2023 second extraordinary general meeting of shareholders of Heyuan Biotechnology (Shanghai) Co., Ltd. It details the meeting date, attendance, voting results on various proposals, and legal witness statements. There is no financial data or report content, only the official voting results and meeting procedural information. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes, not a full report or presentation.
2023-12-26 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.